Malignant neoplasm of lower lobe, right bronchus or lung
ICD-10 C34.31 is a billable code used to indicate a diagnosis of malignant neoplasm of lower lobe, right bronchus or lung.
C34.31 refers to a malignant neoplasm located in the lower lobe of the right lung or bronchus. This diagnosis is commonly associated with lung cancer, which is characterized by uncontrolled cell growth in lung tissues. The primary risk factor for lung cancer is a history of smoking, with both active and passive exposure contributing significantly to the disease's incidence. Staging of lung cancer is crucial for determining treatment options and prognosis, typically classified using the TNM system, which assesses tumor size (T), lymph node involvement (N), and metastasis (M). Molecular markers, such as EGFR mutations and ALK rearrangements, play a vital role in guiding targeted therapies. Treatment algorithms often include a combination of surgery, chemotherapy, radiation therapy, and immunotherapy, depending on the stage and specific characteristics of the tumor. Accurate coding of C34.31 requires thorough documentation of the patient's smoking history, staging details, and any molecular testing results to ensure appropriate treatment and reimbursement.
Detailed pathology reports, imaging studies, and treatment plans.
Initial diagnosis of lung cancer, staging workup, treatment planning.
Ensure all molecular testing results are documented for targeted therapies.
Pulmonary function tests, imaging, and smoking history.
Evaluation of lung nodules, management of lung cancer patients.
Document any comorbid respiratory conditions that may affect treatment.
Used when a patient with lung cancer presents with pleural effusion.
Document the indication for the procedure and any imaging guidance used.
Pulmonologists should ensure proper technique and follow-up care.
Staging is crucial as it determines the extent of the disease, guides treatment options, and influences prognosis. Accurate staging must be documented to support the coding of C34.31.
